Search results
Showing 271 to 285 of 1331 results for heart OR cardi* OR arrythmia
research into efficacy of extracorporeal membrane oxygenation (ECMO) for acute heart failure. This should include clear documentation of...
This quality standard covers identifying and managing familial hypercholesterolaemia (FH) in children, young people and adults. FH is a type of high cholesterol that runs in families and increases the risk of heart disease. The quality standard describes high-quality care in priority areas for improvement.
View quality statements for QS41Show all sections
Sections for QS41
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Specialist referral
- Quality statement 3: DNA testing
- Quality statement 4: Diagnosis in children under 10 years
- Quality statement 5: Cascade testing
- Quality statement 6: Drug treatment in adults
- Quality statement 7: Drug treatment in children
Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)
NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .
Visensia for early detection of deteriorating vital signs in adults in hospital (MIB36)
NICE has developed a medtech innovation briefing (MIB) on Visensia for early detection of deteriorating vital signs in adults in hospital
Making a positive impact: people and communities network case studies
Making a positive impact: NICE people and communities network case studies
Making a positive impact: people and communities network case studies
Making a positive impact: NICE people and communities network case studies
Familial hypercholesterolaemia: identification and management (CG71)
This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)
NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .
Thermogard XP for therapeutic hypothermia after cardiac arrest (MIB37)
NICE has developed a medtech innovation briefing (MIB) on Thermogard XP for therapeutic hypothermia after cardiac arrest
and efficacy of permanent His-bundle pacemaker implantation for treating heart failure is inadequate in quality and quantity.Therefore,...
thousands monitor heart condition from home A wireless sensor the size of a paperclip could transform care for people living with...
Balloon dilatation of systemic to pulmonary arterial shunts in children (HTG48)
Evidence-based recommendations on balloon dilatation of systemic to pulmonary arterial shunts in children. This involves inflating a balloon inserted into the area so blood can flow through more easily.
View recommendations for HTG48Show all sections
Sections for HTG48
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions
Angina and coronary heart disease: anti-platelet or anticoagulation (IND132)
This indicator covers the percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM88.